Abstract: The present disclosure relates to methods of modulating level of pathogenic E. coli (EHEC, EPEC, APEC) present in the gastrointestinal tract of an animal by administering saccharide compositions comprising an anhydro moiety. The presence/load with pathogenic E. coli strains can be assessed via the level of LEE and non-LEE pathogenic genes in the microbiome of the host animal.

Abstract: The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome improve the health and welfare of the animal. The present disclosure further relates to methods of modulating level of secondary metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level of tryptophan metabolism derivates.

Abstract: A method and system are provided to facilitate the commissioning of a distributed system. The method and system obtains a base configuration which defines an expected virtual topology for a distributed system, and identifies via a control device a physical network topology of the distributed system to commission the distributed system. The control device performs network discovery to identify a plurality of connected devices that are communicatively coupled thereto, and to collect device information for each connected device relating to its identity and relative position in the distributed system which has connected devices or associated subnetworks connected in a ring network topology. The collected device information for the plurality of connected devices is compared to the expected virtual topology from the base configuration to determine an identity and physical location of the plurality of connected devices and associated subnetworks in the physical network topology of the distributed system.

Abstract: The present disclosure relates to methods of modulating level of E. coli present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level of LEE and non-LEE pathogenic genes in the microbiome of the host animal. The present disclosure further relates to methods of modulating the virulence of pathogenic E. coli in the gastrointestinal tract of an animal by reducing the population of B. thetaiotaomicron in the gut microbiome of the animal.

Abstract: The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut micro-biome improve the health and welfare of the animal. The present disclosure further relates to methods of modulating level of secondary metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level of tryptophan metabolism derivates.

Abstract: In some aspects, the disclosure is directed to methods and systems for identifying a set of predictor metabolites which are predictive of a state of an animal subject. For that purpose, a plurality of data sets of respective ones of a plurality of animal subjects may be obtained, wherein each of the plurality of data sets comprises measurement data comprising an indication of a concentration of each of a plurality of metabolites in a sample of a microbiome of a respective animal subject. A label may be provided at least in part characterizing the state of the animal subject. A feature selection process may be applied to the plurality of data sets to select and thereby identify a subset of the plurality of metabolites of which subset the concentrations are a statistically significant predictor of the state according to the label.

Abstract: A satellite Automatic Identification System (AIS) for tracking maritime vessels includes a constellation of Low-Earth Orbit (LEO) satellites. Each LEO satellite includes an AIS payload for receiving AIS messages from the maritime vessels and determining therefrom reported vessel position data and satellite-based observation data. The system also includes an AIS reporting system configured to obtain the reported maritime vessel position data and satellite-based observation data from the LEO satellites over time. In addition, the AIS reporting system is configured to filter the reported maritime vessel position data and satellite-based observation data to recursively produce estimated maritime vessel positions and update the estimated maritime vessel positions for the maritime vessels.

Abstract: Examples relate to a method, an apparatus and a computer program for processing a plurality of electronic messages, and to an electronic message server. The method comprises obtaining (110) the plurality of electronic messages. The method further comprises selecting (120) at least a subset of electronic messages of the plurality of electronic messages based on information related to a plurality of suspicious electronic message sender identifiers. The method further comprises determining (130), whether a number of electronic messages of the subset of electronic messages obtained within a pre-defined time interval exceeds a threshold. The method further comprises discarding (140) the electronic messages of the subset of electronic messages if the number of electronic messages of the subset of electronic messages obtained within the pre-defined time interval exceeds the threshold.

Abstract: A satellite Automatic Identification System (AIS) for tracking maritime vessels includes a constellation of Low-Earth Orbit (LEO) satellites. Each LEO satellite includes an AIS payload for receiving AIS messages from the maritime vessels and determining therefrom reported vessel position data and satellite-based observation data. The system also includes an AIS reporting system configured to obtain the reported maritime vessel position data and satellite-based observation data from the LEO satellites over time. In addition, the AIS reporting system is configured to filter the reported maritime vessel position data and satellite-based observation data to recursively produce estimated maritime vessel positions and update the estimated maritime vessel positions for the maritime vessels.

Abstract: Provided herein are methods for a novel combination therapy for treating a glutamine-addicted cancer in a subject in need thereof, which comprises the administration of a glutaminase antagonist and a pro-apoptotic compound. Specific glutaminase antagonists and pro-apoptotic compounds are provided. In some embodiments, the glutaminase antagonist is 6-diazo-5-oxo-1-norleucine (DON) and the pro-apoptotic compound is a Bcl-2 family member antagonist. In some embodiments, the pro-apoptotic compound is obatoclax mesylate, navitoclax, or fenretinide. In some embodiments, the glutamine-addicted cancer is a cancer in which Myc is deregulated. In some embodiments, the cancer is a pediatric cancer.

Abstract: A method, apparatus and computer program product for performing automatic enterprise software upgrades is presented. An install agent application of a target system authorizes a centralized controller to securely communicate with the target system. The install agent downloads an upgrade for an enterprise software application installed on said target system from the centralized controller and executes the upgrade for an enterprise software application installed on the target system.

Abstract: The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of acetyl-CoA carboxylase enzyme(s) in an animal.

Abstract: The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of acetyl-CoA carboxylase enzyme(s) in an animal.

Abstract: The invention relates to compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein: A is a moiety of formula: and to pharmaceutically acceptable salts and solvates thereof, wherein X, Z, D, E, V, W, Y, R1, R2, R5, R6, L, and u are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula I to a patient in need thereof, and to compositions for treating such disorders which contain the compounds of formula I. The invention also relates to methods of making the compounds of formula I.

Abstract: The present invention relates to N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors of the formula wherein ring X is a 5-7 membered heterocyclic ring, and wherein A, Y, B, and G are as defined in the specification; and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.

Abstract: The present invention relates to N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors of the formula 1